There are many treatment options for bladder cancer, but surgery is a frequently used treatment, and some bladder cancer patients want to know about post-operative diet
If pancreatic cancer is not treated in time, it will develop and become more and more serious as the disease progresses, and because the symptoms of pancreatic cancer are sometimes not obvious in the early stages of the disease, the disease is diagnosed in the middle and late stages.
Everyone wants to be in good health because we all know that good health is the only way to live a better life. However, many diseases still occur frequently nowadays, so we need to know about the common diseases
Pancreatic cancer is a very complex and common tumour of the pancreas, and the malignancy of this disease is relatively high.
H-Drugs in the leading international journal again!
If you want to confirm the diagnosis of nasopharyngeal cancer, you need to go to a hospital for examination. You can go to the ENT department of a regular hospital near you, or you can go to the oncology department for examination.
Nasopharyngeal cancer is a very complex disease that causes abnormal symptoms in the ears and nose, which can seriously affect the health and living conditions of patients with nasopharyngeal cancer.
Alveolar rhabdomyosarcoma is a rare but very deadly childhood tumour, and for more than 40 years there have been no new advances in the treatment of this disease. Recently, a study led by Professor Anton Henssen of the Charité University of Berlin has identified a promising new treatment for the disease.
A new study shows that for a common type of skin cancer, squamous cell carcinoma of the skin, immunotherapy before surgery resulted in the complete disappearance of tumours in 50.6% of patients and more than 90% in 12.7% of patients.
The European Union has approved the marketing of the new treatment Opdualag for the treatment of melanoma patients. New data demonstrates that the treatment resulted in the complete disappearance of tumours in 16.3% of patients, a significant reduction in tumours in 26.8% and stable disease without further progression in 18.2% of patients, giving an efficiency rate of 61.3%.
